485 Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors by Thomas Davis, Jessica Price, Mark Awad, Ammar Sukari, Roger Cohen, Mark Stein, Przemyslaw Twardowski, Jessica Flechtner, Melissa Johnson, Maura Gillison, Rudy Lackner, Arthur DeCillis, Richard Hernandez, Kevin Mancini, Mara Shainheit, Gabriella Santone, Syukri Shukor, Ece Bicak, Vijetha Vemulapalli, Emily Tjon